Novartis to acquire Chinook Therapeutics for US$3.2 B to Bolster Kidney Disease Portfolio
By Lucy Haggerty
Pharma Deals Review: Vol 2023 Issue 6 (Table of Contents)
Published: 20 Jun-2023
DOI: 10.3833/pdr.v2023.i6.2793 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
In a bid to bolster its rare kidney disease portfolio, Novartis has agreed to acquire Chinook Therapeutics for US$3...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS